Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 4/2023

01-12-2023 | Trastuzumab | editorial

HER2 in focus—gastric cancer

Author: Dr. Aysegül Ilhan-Mutlu

Published in: memo - Magazine of European Medical Oncology | Issue 4/2023

Login to get access

Excerpt

Human epidermal growth factor receptor 2 (HER2) was the first molecule targeted by monoclonal antibodies in solid disease. Interestingly, the first patients with disseminated HER2-positive metastatic breast cancer who received the anti-HER2 drug trastuzumab in phase I trials in the early 1990s are still alive (Siddhartha Mukharjee, The Emperor of All Maladies, A Biography of Cancer, Scribner, New York, NY, USA). This opened the door for several investigations to identify other biomarkers for targeted therapies, which significantly changed the treatment armamentarium of several types of cancer. …
Literature
1.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97.
2.
Ilhan-Mutlu A. Second line treatment of HER2 positive advanced gastroesophageal adenocarcinoma: past, present and future. memo. 2023;16(4).
3.
Roider-Schur S, Machat S, Öhler L. Fast and significant response to Her2-directed therapy in the 5th line in a patient with HER2-positive metastatic adenocarcinoma of the gastroesophageal junction—A case report. memo. 2023;16(3).
Metadata
Title
HER2 in focus—gastric cancer
Author
Dr. Aysegül Ilhan-Mutlu
Publication date
01-12-2023
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 4/2023
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00925-x

Other articles of this Issue 4/2023

memo - Magazine of European Medical Oncology 4/2023 Go to the issue

case report

Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction

editorial

Supportive management

short review

ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma

original report

WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients

comment

Comment to Smith MR, Hussain M, Saad F et al. (2022, N Engl J Med) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

short review

Management of malignant hypercalcemia in cancer patients—a short review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits